Periodontal treatment in delaying End-stage renal diseases among chronic kidney disease patients

Effectiveness of Subgingival Instrumentation on delaying End-stage renal diseases among chronic kidney disease patients: A Non-Randomised Clinical Study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/07/114079

Enrollment

Registered

2026-07-15

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N184- Chronic kidney disease, stage 4 (severe)

Interventions

Intervention1: Subgingival Instrumentation: Participants will receive subgingival instrumentation using an ultrasonic scaler (NSK Variose 2 Ultrasonic Scaler) and hand instruments (Sickle scalers and

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 40 to 70 years. Type 2 diabetes mellitus with chronic kidney disease and currently on oral hypoglycaemic agents. Diagnosed with Stage IV chronic kidney disease with eGFR between 15 and 20 mL per min per 1.73 m2. Not undergoing dialysis. Presence of at least 20 natural teeth. Diagnosed with Stage II periodontitis according to the 2017 World Workshop Classification with interdental clinical attachment loss at the site of greatest loss greater than 2 mm but less than 5 mm in at least 2 non-adjacent teeth. Willing to provide written informed consent.

Exclusion criteria

Exclusion criteria: Patients already undergoing haemodialysis or renal transplantation. Patients on insulin therapy or taking SGLT2 inhibitors and GLP 1 receptor agonists. Glycated haemoglobin HbA1c level greater than 8 percent. Any periodontal therapy within the past 6 months. Immunocompromised patients. Any history of tobacco use. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Change in Estimated Glomerular Filtration Rate eGFRTimepoint: Baseline,3,6,9,12 months	—

Secondary

Measure	Time frame
Change in suPAR Soluble urokinase plasminogen Activator ReceptorTimepoint: Baseline and 12 months;Change in periodontal markers including Pocket Probing Depth PPD, Clinical Attachment Loss CAL, Bleeding on Probing BOP, Calculus Component of Oral Hygiene IndexTimepoint: Baseline,3,6,9,12 months;Change in Renal parameters including Serum creatinine, Serum albumin and Serum ureaTimepoint: Baseline,3,6,9,12 months;Percentage of Chronic Kidney Disease patients progressing from pre-dialysis to dialysis.Timepoint: Baseline to 12 months;Association of serum biochemical markers with periodontal markers and renal parametersTimepoint: Baseline,3,6,9,12 months;Change in the concentration of high-sensitivity C-reactive protein hs-CRP in plasmaTimepoint: Baseline,3,6,9,12 months;Change in HbA1c levelsTimepoint: Baseline,3,6,9,12 months	—

Measure

Time frame

Change in suPAR Soluble urokinase plasminogen Activator ReceptorTimepoint: Baseline and 12 months;Change in periodontal markers including Pocket Probing Depth PPD, Clinical Attachment Loss CAL, Bleeding on Probing BOP, Calculus Component of Oral Hygiene IndexTimepoint: Baseline,3,6,9,12 months;Change in Renal parameters including Serum creatinine, Serum albumin and Serum ureaTimepoint: Baseline,3,6,9,12 months;Percentage of Chronic Kidney Disease patients progressing from pre-dialysis to dialysis.Timepoint: Baseline to 12 months;Association of serum biochemical markers with periodontal markers and renal parametersTimepoint: Baseline,3,6,9,12 months;Change in the concentration of high-sensitivity C-reactive protein hs-CRP in plasmaTimepoint: Baseline,3,6,9,12 months;Change in HbA1c levelsTimepoint: Baseline,3,6,9,12 months

—

Countries

India

Contacts

Public ContactDr Gurleen Kaur

Pandit Bhagwat Dayal Sharma Post Graduate Institute of Dental Sciences Rohtak

vipulyadavv.97@gmail.com8826363961

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026